Page 40 - அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update - Phase 1 AUGMENT-101 data expected in late 1Q21 or early 2Q21; Phase 2 expansion cohorts expected to commence in 2Q21 - - Enrollment underway in pivotal Phase 2 AGAVE-201 trial of axatilimab in cGVHD - - End of year cash balance of $293.1 million provides cash runway into 2023- - Company to host conference call today at 4:30 p.m. ET - News provided by Share this article Share this article WALTHAM, Mass., March 8, 2021 /PRNewswire/  Syndax Pharmaceuticals, Inc. ( Syndax, the Company or we ) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2020. In addition, the Company provided a clinical and business update.

United statesBriggsw morrisonEytanm steinMelissa forstExchange commissionAmerican society of hematologyInternational numberSyndax pharmaceuticalsProgram for drug development in leukemiaSyndax pharmaceuticals incChief executive officerAttending physicianDrug developmentMemorial sloan kettering cancer centerAmerican societyAnnual meeting